



Drug Coverage Decision for BC PharmaCare

About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

Details of Drug Reviewed

Drug	Lebrikizumab
Brand name	Ebglyss™
Dosage form(s)	250 mg/ 2mL prefilled pen or prefilled syringe
Manufacturer	Eli Lilly Canada, Inc.
Submission type	Resubmission
Indication reviewed	For the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Canada's Drug Agency (CDA-AMC) Clinical Reimbursement Reviews (CRR)	The Canadian Drug Expert Committee (CDEC) recommended: to Reimburse with clinical criteria and/or conditions . Visit the CDA-AMC website for more details .
Ministry of Health (the Ministry) Review	The Ministry reviewed clinical and pharmacoeconomic combined reports prepared by the CDA-AMC's CRR , including clinical and pharmacoeconomic evidence review material and the recommendations of the CDEC. The Ministry also considered patient input provided to CDEC.
Drug Coverage Decision	Limited Coverage benefit
Date	August 5 th , 2026
Reason(s)	Drug coverage decision is consistent with the CDEC recommendation that Ebglyss be reimbursed, with conditions, for the treatment of moderate-to-

severe atopic dermatitis in adults and adolescents 12 years of age and older, weighing at least 40 kg.

- CDA-AMC previously recommended not to reimburse Ebglyss. This resubmission included new evidence to address evidence gaps identified by CDEC related to longer-term safety and efficacy and comparative clinical value versus other targeted systemic therapies for atopic dermatitis.
- Previously reviewed evidence from 3 clinical trials showed that, in the short term, Ebglyss reduced AD severity and itching compared to placebo in adults and adolescents with moderate to severe AD.
- Based on the new evidence submitted, CDEC determined that Ebglyss demonstrates acceptable clinical value versus other targeted systemic therapies used for the treatment of moderate-to-severe atopic dermatitis.
- New longer-term evidence suggested that efficacy may be sustained for up to 100 weeks with no new safety concerns, although uncertainty remains due to limitations in the evidence.
- At the manufacturer's list price, Ebglyss is not considered cost-effective unless its drug program cost does not exceed the cost of the least costly targeted systemic therapy for the same indication.
- A pCPA agreement for lebrikizumab was already in place following successful negotiations concluded in 2025. BC and other jurisdictions can opt in to the existing agreement which is able to address the concerns identified by CDEC with respect to cost.

The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent national organization called Canada's Drug Agency (CDA-AMC) provides evidence-based recommendations to public drug plans across Canada through its reimbursement review process. As part of the CDA-AMC's Clinical Reimbursement Review process, the Canadian Drug Expert Committee (CDEC) makes reimbursement recommendations for non-oncology pharmaceuticals to the participating federal, provincial, and territorial publicly funded drug plans. In developing its recommendations, the CDEC considers:

- whether the drug is safe and effective
- what the drug costs and whether funding it provides good value
- ethical considerations of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by considering:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the CDA-AMC
- the recommendations and reimbursement conditions of the CDEC
- if a Ministry Initiated review, the advice of an independent expert group called the Drug Benefit Council (DBC)
- BC-specific patient input collected through the Your Voice website
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug
- the outcomes of pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with manufacturers

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.